Posted by Michael Wonder on 21 Aug 2025
Dawnzera (donidalorsen) approved in the US as first and only RNA targeted prophylactic treatment for hereditary angioedema
21 August 2025 - Offers longest dosing option for hereditary angioedema, with dosing every 4 or 8 weeks.
Ionis Pharmaceuticals announced today that the US FDA has approved Dawnzera (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema in adult and paediatric patients 12 years of age and older.
